- Home
- AMBP vs MIRM Comparison
AMBP vs MIRM Comparison
Compare AMBP & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMBP
- MIRM
- Stock Information
- Founded
- AMBP 2021
- MIRM 2018
- Country
- AMBP Luxembourg
- MIRM United States
- Employees
- AMBP N/A
- MIRM N/A
- Industry
- AMBP Containers/Packaging
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- AMBP Industrials
- MIRM Health Care
- Exchange
- AMBP Nasdaq
- MIRM Nasdaq
- Market Cap
- AMBP 2.6B
- MIRM 2.5B
- IPO Year
- AMBP N/A
- MIRM 2019
- Fundamental
- Price
- AMBP $4.75
- MIRM $52.66
- Analyst Decision
- AMBP Buy
- MIRM Strong Buy
- Analyst Count
- AMBP 4
- MIRM 9
- Target Price
- AMBP $4.26
- MIRM $66.22
- AVG Volume (30 Days)
- AMBP 1.8M
- MIRM 456.2K
- Earning Date
- AMBP 07-24-2025
- MIRM 08-06-2025
- Dividend Yield
- AMBP 8.43%
- MIRM N/A
- EPS Growth
- AMBP N/A
- MIRM N/A
- EPS
- AMBP N/A
- MIRM N/A
- Revenue
- AMBP $5,035,000,000.00
- MIRM $379,251,000.00
- Revenue This Year
- AMBP $8.25
- MIRM $35.83
- Revenue Next Year
- AMBP $2.32
- MIRM $16.83
- P/E Ratio
- AMBP N/A
- MIRM N/A
- Revenue Growth
- AMBP 4.42
- MIRM 69.31
- 52 Week Low
- AMBP $2.50
- MIRM $36.17
- 52 Week High
- AMBP $4.78
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- AMBP 81.53
- MIRM 64.66
- Support Level
- AMBP $4.24
- MIRM $49.22
- Resistance Level
- AMBP $4.78
- MIRM $53.86
- Average True Range (ATR)
- AMBP 0.10
- MIRM 1.57
- MACD
- AMBP 0.03
- MIRM 0.08
- Stochastic Oscillator
- AMBP 93.28
- MIRM 79.63
About AMBP Ardagh Metal Packaging S.A.
Ardagh Metal Packaging SA is a supplier of infinitely recyclable, sustainable, metal beverage cans and ends to brand owners. The company deals with multiple categories of products including beer, carbonated soft drinks, energy drinks, hard seltzers, juices, pre-mixed cocktails, teas, sparkling waters, and wine. Its segment includes Europe and the Americas. It derives a majority of its revenue from the Americas.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.